Arrotex becomes Australia’s largest generic pharmaceutical and private label OTC business.
Arrow Pharmaceuticals and Apotex Australia have today become one, with Dennis Bastas, CEO and part-owner of the newly formed Arrotex, assuring customers of both brands that it will be “business as usual”.
Arrotex is also jointly owned by Canada-based Apotex Inc, with Strides Pharma Science Limited agreeing to sell down its interest in Arrow Pharmaceuticals to Bastas when the merger was first announced in May 2018.
“Both companies respect and value the relationship that pharmacists and consumers have with the Arrow and Apotex products and brands,” Bastas said today.
“Our customers can rest assured that there will be no change in the way that they do business with us and that the merged business will continue to provide all the Arrow and Apotex brands that people have come to trust, including the Chemist’s Own and Apo-Health OTC ranges,” he said.
Strides will continue to be a major supplier to Arrotex, as the company’s largest generic pharmaceutical supply partner.
Bastas said Arrotex products will account for almost 30% of all prescription volume dispensed in pharmacies across Australia, and thanked staff, customers and business partners for their patience and support through the 18 month merger period.
More in tomorrow’s issue of Pharmacy Daily.
